Here are the S-3 shelf registrations from Galectin Therapeutics Inc. (GALT) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow GALT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GALT filings page.
Galectin Therapeutics Inc. filed a shelf registration on Form S-3 to offer up to $200,000,000 of common stock, warrants and rights. Under a prospectus supplement the company established an at-the-market (ATM) program with H.C. Wainwright to sell up to $32,500,000 of common stock. The supplement estimates up to 11,363,636 shares based on a $2.86 per-share price and states Wainwright will receive a 3.0% selling commission.
The prospectus describes the NAVIGATE Phase 2b/3 study results for belapectin, noting a 49.3% reduction in varices in the per-protocol population (n=287) and a 68.1% reduction (p=0.02) in the U.S. completer subgroup. Shares outstanding are listed as 65,827,448 as of March 16, 2026 (and 65,201,995 as of December 31, 2025 in dilution examples).